Polycythemia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
* Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies. | |||
*Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies. | |||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States. | |||
*The [[incidence]] of [[polycythemia vera]] is approximately 1.9 per 100,000 individuals in the United States. | |||
*Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | *Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of polycythemia vera | |||
*Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | *The [[prevalence]] of [[Polycythemia vera|polycythemia vera i]]<nowiki/>n the 7 MM countries was 283,442 in 2017. | ||
*[[Prevalence]] of [[polycythemia vera]] was the highest in the US in 2017 at 157,290, out of which 62,916 cases were [[asymptomatic]] and 94,374 were [[symptomatic]]. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | |||
*22 cases per 100,000 people. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | *22 cases per 100,000 people. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
* 4-year mortality rate is >10%. | |||
*4-year [[Mortality rate|mortality]] rate is >10%. | |||
*On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | *On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | ||
*Comorbidities such as cardiovascular diseases, other blood, and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc accounted for more deaths more often. | *[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often. | ||
*Thrombotic complications were the most common cause of death followed by hematologic malignancy. <ref name="urlwww.hematologyadvisor.com">{{cite web |url=https://www.hematologyadvisor.com/home/conference-coverage/ash-2020/assessing-mortality-rates-causes-of-death-in-polycythemia-vera/ |title=www.hematologyadvisor.com |format= |work= |accessdate=}}</ref> | *[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]]. <ref name="urlwww.hematologyadvisor.com">{{cite web |url=https://www.hematologyadvisor.com/home/conference-coverage/ash-2020/assessing-mortality-rates-causes-of-death-in-polycythemia-vera/ |title=www.hematologyadvisor.com |format= |work= |accessdate=}}</ref> | ||
===Age=== | ===Age=== | ||
*It has been noted that PV is more common in the age group >75. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | *It has been noted that PV is more common in the age group >75. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | ||
*Median age of diagnosis is 60. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | *Median age of diagnosis is 60. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | ||
===Race=== | ===Race=== | ||
*Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | *Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. <ref name="urlwww.lls.org">{{cite web |url=https://www.lls.org/sites/default/files/file_assets/FS13_PolycythemiaVera_FactSheet_final5.1.15.pdf |title=www.lls.org |format= |work= |accessdate=}}</ref> | ||
===Gender=== | ===Gender=== | ||
*Generally, there is no sex | |||
*Generally, there is no sex predilection.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | |||
*In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | *In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. <ref name="urlPolycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs">{{cite web |url=https://www.globenewswire.com/news-release/2020/07/15/2062391/0/en/Polycythemia-Vera-PV-Trends-Epidemiology-2017-2030-KOL-Views-and-Unmet-Needs.html |title=Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs |format= |work= |accessdate=}}</ref> | ||
===Region=== | ===Region=== | ||
*Incidence of cases is higher in the United States and Europe than in Japan. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref>. <ref name="pmid16673273">{{cite journal |vauthors=Johansson P |title=Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia |journal=Semin Thromb Hemost |volume=32 |issue=3 |pages=171–3 |date=April 2006 |pmid=16673273 |doi=10.1055/s-2006-939430 |url=}}</ref> | *Incidence of cases is higher in the United States and Europe than in Japan. <ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref>. <ref name="pmid16673273">{{cite journal |vauthors=Johansson P |title=Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia |journal=Semin Thromb Hemost |volume=32 |issue=3 |pages=171–3 |date=April 2006 |pmid=16673273 |doi=10.1055/s-2006-939430 |url=}}</ref> | ||
Revision as of 16:19, 2 March 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
- Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies.
Epidemiology and Demographics
Incidence
- The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States.
- Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. [1]
Prevalence
- The prevalence of polycythemia vera in the 7 MM countries was 283,442 in 2017.
- Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic. [2]
- 22 cases per 100,000 people. [1]
Case-fatality rate/Mortality rate
- 4-year mortality rate is >10%.
- On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
- Comorbidities such as cardiovascular diseases, other blood, and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc. accounted for more deaths more often.
- Thrombotic complications were the most common cause of death followed by hematologic malignancy. [3]
Age
- It has been noted that PV is more common in the age group >75. [2]
- Median age of diagnosis is 60. [4]
Race
- Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. [1]
Gender
- Generally, there is no sex predilection.[4]
- In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. [2]
Region
Developed Countries
Developing Countries
References
- ↑ 1.0 1.1 1.2 "www.lls.org" (PDF).
- ↑ 2.0 2.1 2.2 "Polycythemia Vera (PV): Trends, Epidemiology (2017-2030), KOL Views and Unmet Needs".
- ↑ "www.hematologyadvisor.com".
- ↑ 4.0 4.1 4.2 Lu X, Chang R. PMID 32491592 Check
|pmid=value (help). Missing or empty|title=(help) - ↑ Johansson P (April 2006). "Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia". Semin Thromb Hemost. 32 (3): 171–3. doi:10.1055/s-2006-939430. PMID 16673273.